Bristol Myers Squibb (BMY) is a publicly traded Healthcare sector company. As of May 20, 2026, BMY trades at $58.52 with a market cap of $117.03B and a P/E ratio of 16.83. BMY moved +0.20% today. Year to date, BMY is +9.07%; over the trailing twelve months it is +23.49%. Its 52-week range spans $42.52 to $63.33. Analyst consensus is buy with an average price target of $64.29. Rallies surfaces BMY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Bristol-Myers Squibb Deploys Anthropic Claude AI to 30,000 Employees for Drug Discovery: Bristol-Myers Squibb is deploying Anthropic’s Claude AI model to over 30,000 employees across research, development and commercial teams to accelerate drug discovery workflows. The program will integrate generative AI into target identification, hit optimization and project decision-making to reduce R&D costs and shorten development timelines.
| Metric | Value |
|---|---|
| Price | $58.52 |
| Market Cap | $117.03B |
| P/E Ratio | 16.83 |
| EPS | $3.47 |
| Dividend Yield | 0.63% |
| 52-Week High | $63.33 |
| 52-Week Low | $42.52 |
| Volume | 5.21M |
| Avg Volume | 0 |
| Revenue (TTM) | $48.19B |
| Net Income | $7.05B |
| Gross Margin | 71.08% |
18 analysts cover BMY: 0 strong buy, 6 buy, 12 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $64.29.